GVRP and Yurogen Biosystems Partner to Expand Antibody Discovery Services in India

GV Research Platform (GVRP) announced a strategic distribution partnership with Yurogen Biosystems, a global life sciences company specialising in custom biologics development. The collaboration is aimed at expanding access for Indian biotechnology and pharmaceutical companies, as well as academic research institutions, to advanced antibody discovery capabilities supporting early-stage drug discovery and translational research.

Under this partnership, GVRP will serve as the commercial interface for Yurogen Biosystems in India, enabling streamlined market access, client engagement, and program coordination, while all scientific execution and service delivery will continue to be carried out by Yurogen Biosystems.

The collaboration responds to the growing demand within India's life sciences ecosystem for globally benchmarked antibody discovery services, particularly in areas requiring deep biological insight at early stages of research. By combining Yurogen's scientific expertise with GVRP's understanding of the Indian research ecosystem, the partnership enables smoother and more efficient engagement for domestic innovators.

The partnership provides access to Yurogen Biosystems' proprietary SMab™ single B-cell technology, enabling rapid generation of high-affinity monoclonal antibodies to support early discovery and translational research programs. The platform offers customised antibody engineering and production supported by comprehensive antibody-based solutions for research, diagnostics, and antibody-related drug development applications.

Development capabilities include rabbit, camelid (llama), and fully human monoclonal antibodies tailored for diverse biological targets and therapeutic strategies. Optimised workflows are designed to reduce development timelines while maintaining high performance, reproducibility, and scientific rigor required for early-stage biologics research.

Engagement models are designed to ensure clarity on ownership and freedom to operate, with antibody clones and related research outputs delivered without IP encumbrances from the platform.

The Co-Founder & CEO of GV Research Platform stated that the partnership reflects a focus on expanding meaningful access to advanced monoclonal antibody discovery platforms such as SMab™. As the local commercial interface, GVRP will simplify engagement and facilitate access to globally benchmarked discovery capabilities. The CEO of Yurogen Biosystems noted that India is emerging as an important centre for early-stage biomedical research, and partnering with GVRP allows closer engagement with the Indian biopharma community through a trusted local presence.